SCHEMBL701960

SCHEMBL701960

COC(=O)c1ccoc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.59
GAA P10253 2/20 0.59
HPGD P15428 2/20 0.59
TSHR P16473 3/20 0.53
MAPK1 P28482 1/20 0.53
ESR2 Q92731 1/20 0.53
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 3/20 0.51
NPC1 O15118 3/20 0.51
PKM P14618 1/20 0.51
KMT2A Q03164 3/20 0.50
HTT P42858 2/20 0.50
MEN1 O00255 2/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18494022 0.82 RAB9A (0.50) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL1757222 0.80 ALDH1A1 (0.60) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL69723 0.79 HSD17B10 (0.44) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL165259 0.79 HSD17B10 (0.44) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL28474528 0.78 MAPK1 (0.55) HPGDTSHRMAPK1ESR2RAB9A
SCHEMBL31310778 0.78 HSD17B10 (0.43) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL19475277 0.78 ABL1 (0.44) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL2418235 0.78 HSD17B10 (0.43) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL6410207 0.78 HSD17B10 (0.43) HSD17B10GAAHPGDTSHRMAPK1
SCHEMBL12644123 0.78 ALDH1A1 (0.50) HSD17B10GAAHPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108383828-A 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative 阿勒根公司 2018-08-10 CN claimed
EP-2955173-B1 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2017-10-04 EP claimed
US-9603834-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2017-03-28 US claimed
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. 2016-08-11 US claimed
EP-2955173-A1 NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2015-12-16 EP claimed
EP-2651901-B1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2015-05-27 EP claimed
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-08-07 US claimed
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-02-20 US claimed
CN-103384662-A Novel 1, 2-bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN INC 2013-11-06 CN claimed
EP-2651901-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS Allergan, Inc. (US) 2013-10-23 EP claimed
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 US claimed
WO-2012082633-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
US-20050124684-A1 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
EP-4739688-A2 TRIAZOLO WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-05-13 EP disclosed
EP-4727942-A2 THIAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-04-22 EP disclosed
US-4215057-A Process for the production of substituted furans CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1980-07-29 US disclosed
US-4201715-A Process for the anilidization of carboxylic acid esters WACKER-CHEMIE GMBH (DE) 1980-05-06 US disclosed
US-4187237-A Process for the manufacture of a furancarboxylic acid anilide CONSORTIUM FOR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1980-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 HSD17B10 3808/4885GAA 4465/4885HPGD 1083/4885
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD HSD17B10 1460/4885GAA 2485/4885HPGD 309/4885
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 HSD17B10 3808/4885GAA 4465/4885HPGD 1083/4885
US-20050124684-A1 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production TNF, IL1A, IL1B HSD17B10 438/4885GAA 1618/4885HPGD 31/4885
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 HSD17B10 3808/4885GAA 4465/4885HPGD 1083/4885
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 HSD17B10 3808/4885GAA 4465/4885HPGD 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.